NEW YORK (GenomeWeb News) – Expression Pathology will collaborate with the Tom Baker Cancer Centre in Alberta, Canada, to identify breast cancer metastasis biomarkers, EPI said today.
The project is being funded with CAD$300,000 ($288,000) from the Alberta Cancer Board.
EPI said it will use its tissue proteomics technologies to study archived formalin-fixed breast cancer tissue samples taken from patients treated at the cancer center. The company’s Liquid Tissue sample preparation and Director laser microdissection technologies will enable in-depth mass spectrometry analysis, the firm said.
“Our project with EPI will strive to identify proteins in primary tumor tissue that may serve as biomarkers of the early stages of metastasis at the molecular level,” Anthony Magliocco, director of pathology at the center and an associate professor of medicine at the University of Calgary, said in a statement.
“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions and to identify new therapeutic targets and companion diagnostics to those targets,” said EPI CEO Casimir Eitner in a statement.